

1 **A Mixed Methods Study Evaluating Acceptability of a Daily COVID-19 Testing Regimen**  
2 **with a Mobile-App Connected, At-Home, Rapid Antigen Test: Implications for Current and**  
3 **Future Pandemics**

4  
5 Nadia Nguyen, PhD<sup>1</sup>  
6 Benjamin Lane, MPH<sup>1</sup> [bvl2110@cumc.columbia.edu](mailto:bvl2110@cumc.columbia.edu)  
7 Sangwon Lee, PhD<sup>2</sup>  
8 Sharon Lipsky Gorman<sup>3</sup>  
9 Yumeng Wu<sup>1</sup>  
10 Alicia Li<sup>4</sup>  
11 Helen Lu, PhD<sup>2</sup>  
12 Noemie Elhadad, PhD<sup>3</sup>  
13 Michael Yin, MD<sup>5</sup>  
14 Kathrine Meyers, DrPH\*<sup>1</sup>

15  
16 \*Corresponding Author  
17 Correspondence to [kam2157@cumc.columbia.edu](mailto:kam2157@cumc.columbia.edu)  
18 Aaron Diamond AIDS Research Center  
19 701 W. 168th Street  
20 HHSC 1102  
21 New York, NY 10032

22  
23 Author affiliations

24  
25 <sup>1</sup> The Aaron Diamond AIDS Research Center, Columbia University  
26 701 W. 168th Street  
27 HHSC 1102  
28 New York, NY 10032

29  
30 <sup>2</sup> Columbia University Department of Biomedical Engineering  
31 1210 Amsterdam Ave  
32 New York, NY 10027

33  
34 <sup>3</sup> Columbia University Department of Biomedical Informatics  
35 622 West 168th Street  
36 PH20 3720  
37 New York, NY 10032

38  
39 <sup>4</sup> Columbia University Vagelos College of Physicians and Surgeons  
40 630 W 168th Street  
41 New York, NY 10032

42  
43 <sup>5</sup> Columbia University Department of Medicine  
44 630 West 168th Street  
45 PH 8 East Room 105  
46 New York, NY 10032

47  
48

49 **Declaration of Interests**

50 The authors declare that they have no competing interests. NN, BL, MY, and KM are involved in  
51 completing clinical studies of the COVID-19 antigen test on behalf of BioMedomics Inc. for  
52 submission to the FDA. SL, SLG, HL, and NE were involved in the development of the paired  
53 mobile application which has been licensed to BioMedomics Inc. BioMedomics had no role in  
54 study design, data collection and analysis, decision to publish, or preparation of the manuscript.  
55 This research did not receive any specific grant from funding agencies in the public,  
56 commercial, or not-for-profit sectors.

57  
58

59 **Abstract: (295/300 words)**

60

61 **Background**

62 Widespread use of at-home rapid COVID-19 antigen tests has been proposed as an important  
63 public health intervention to interrupt chains of transmission. Antigen tests may be preferred  
64 over PCR because they provide on-demand results for relatively low cost and can identify  
65 people when they are most likely to be infectious, particularly when used daily. Yet the extent to  
66 which a frequent antigen testing intervention will result in a positive public health impact for  
67 COVID-19 will depend on high acceptability and high adherence to such regimens.

68 **Methods**

69 We conducted a mixed-methods study assessing acceptability of and adherence to a daily at-  
70 home mobile-app connected rapid antigen testing regimen among employees of a US-based  
71 media company. Acceptability was assessed across seven domains of the Theoretical  
72 Framework of Acceptability.

73 **Results**

74 Among 31 study participants, acceptability of the daily testing intervention was generally high,  
75 with participants reporting high perceived effectiveness, intervention coherence, and self-  
76 efficacy; positive affective attitude; acceptable degree of burden and opportunity cost; and  
77 assessing the intervention as ethical. 71% reported a preference to test daily using an at-home  
78 antigen test than weekly employment-based PCR. Mean adherence to the 21-day testing  
79 regimen was 88% with 43% of participants achieving 100% adherence, 48% testing at least  
80 every other day, and 10% testing less than every other day.

81 **Conclusions**

82 Despite overall high acceptability and adherence, we identified three implementation challenges  
83 that must be addressed for frequent serial testing for COVID-19 to be implemented at scale and  
84 have a positive public health impact. First, users need guidance on how and when to adapt  
85 testing frequencies to different epidemiological conditions. Second, users and institutions need  
86 guidelines for how to safely store and share test results. Third, implementation of serial testing  
87 strategies must prioritize health equity and protect those most vulnerable to COVID-19.

88

89 **Key words:** COVID-19, rapid antigen test, self-test, acceptability

90

91

92 **1.0 Introduction (5409/5500)**

93

94 The use of at-home rapid COVID-19 antigen tests has been identified as an important public  
95 health intervention because such tests provide on-demand results for relatively low cost and can  
96 identify people when they are most likely to be infectious. Although antigen tests are not as  
97 sensitive as molecular tests like real-time PCR for detecting COVID-19, this limitation can be  
98 overcome by testing more frequently, including as often as daily. There is growing evidence from  
99 both modeling (1,2) and real-world studies (3–6) that antigen tests used frequently perform as  
100 well, and in some cases better at controlling the spread of COVID-19, than PCR administered  
101 less frequently.

102

103 Although antigen tests were developed relatively early in the pandemic, with the first at-home  
104 antigen test gaining Food and Drug Administration (FDA) approval for use in the United States  
105 (US) in December 2020 (Figure 1), they have been unavailable and underutilized for much of the  
106 pandemic in favor of more sensitive but also more expensive and time-consuming lab-based PCR  
107 tests (7). In contrast, at-home antigen testing is a cornerstone in COVID-19 control measures in  
108 many European countries, including the UK and Germany, where such tests have been provided  
109 for free or at very low cost and have been widely used (7–9). Recognizing the important role of  
110 at-home antigen tests, the Biden administration has taken a number of steps to significantly  
111 increase the availability and use of at-home antigen tests, including scaling up production of such  
112 tests; investing \$2 billion to distribute free tests throughout the community; selling tests at cost;  
113 mailing free tests to households; and mandating tests be reimbursed through insurers (10–12).  
114 These steps have the potential to dramatically increase the availability of and access to at-home  
115 antigen in the US.

116

117 Yet the extent to which a massive influx of at-home antigen tests to the American public will result  
118 in a positive public health impact will depend on whether and how the tests are used. To date,  
119 there is limited real-world data on the acceptability of at-home antigen testing, particularly when  
120 used serially, where they have been shown to be most effective. Previous implementation studies  
121 of numerous evidence-based interventions, particularly those requiring sustained participation  
122 and adherence, indicate that acceptability is critical to intervention uptake and success (13–15).  
123 Even if at-home antigen tests become widely available, their public health impact will be limited if  
124 frequent testing is not acceptable and adopted at scale. To address this knowledge gap, we  
125 conducted a mixed-methods study informed by Sekhon’s Theoretical Framework of Acceptability  
126 (TFA) (16) to evaluate the acceptability of and adherence to a daily testing regimen among  
127 employees of a large media company in the US.

128

## 129 **2.0 Methods**

130

### 131 **2.1 Research Design**

132 We conducted a mixed-methods observational study from February-June 2021 to examine  
133 factors that influenced the acceptability of and adherence to a serial testing regimen using a  
134 self-administered at-home rapid antigen test (“at-home antigen test”) in a workplace setting  
135 among employees at two divisions of The Walt Disney Company (“Disney”), a media company  
136 based in Southern California in the US. This mixed-methods acceptability study was nested  
137 within a larger parent study (N=93) testing the effectiveness of a daily testing regimen using an  
138 at-home antigen-test against weekly testing with PCR at Disney. Participants in the parent study  
139 were mailed at-home COVID-19 antigen test kits to their home address and asked to self-test  
140 daily for 21 days and, as a condition of their employment, were also concurrently testing at least  
141 weekly for COVID-19 using PCR. In our nested acceptability study, after providing written  
142 informed consent, participants were asked to complete a one-time quantitative survey (N=31),

143 and a subset of participants contributed a one-time qualitative in-depth interview (N=15) at the  
144 conclusion of 21 days of daily testing. Participants had a choice to complete both the  
145 quantitative survey and qualitative interview or just the survey. Participants who completed the  
146 survey were entered into a drawing for a \$100 gift card, and participants who completed the  
147 interview received a \$25 gift card. All study procedures were reviewed and approved by the  
148 Columbia University Irving Medical Center's Institutional Review Board.

149

## 150 **2.2 Recruitment and Study Population**

151 Participants in the acceptability study were informed of the goals of the study and recruited from  
152 the parent study via email. To be eligible for the parent study, participants were 18 years of age  
153 or older; owned a smartphone; understood and read English; had not been diagnosed with  
154 COVID-19 in the past 90 days; had not received any COVID-19 vaccine doses at enrollment;  
155 and were willing to share their weekly PCR results. There were no additional inclusion criteria  
156 for the acceptability study aside from willingness to complete the quantitative survey and being  
157 at least 14 days into the parent. COVID-19 vaccinated employees were excluded because at  
158 the time of recruitment, vaccination was believed to provide strong protection against  
159 breakthrough infections.

160

## 161 **2.3 At-Home Rapid Antigen Test and Mobile App**

162 Participants used an investigational at-home antigen test that is currently under review with the  
163 FDA for Emergency Use Authorization. Test results were available to participants after 15  
164 minutes (for test details, see Appendix A) The test also included a paired smart phone mobile  
165 application (mobile app) that had the following functions: provided step-by-step testing  
166 instructions; captured image of test result and automatically interpret result (positive, negative,  
167 invalid; securely store test result history; and transmit daily test result to the study team.

168

## 169 **2.4 Data Collection**

### 170 *2.4.1 Theoretical Framework*

171 The quantitative survey and in-depth interview questions were informed by Sehkon's Theoretical  
172 Framework of Acceptability (TFA) (16). The TFA defines intervention acceptability as a multi-  
173 faceted construct that reflects the extent to which people consider the health care intervention to  
174 be appropriate, based on anticipated or experienced cognitive and emotional responses to the  
175 intervention. The TFA consists of seven constructs which we adapted to measure the  
176 acceptability of the intervention: affective attitude, burden, perceived effectiveness, ethicality,  
177 intervention coherence, opportunity costs, and self-efficacy (Table 3).

178

### 179 *2.4.2 Adherence to Daily Testing Regimen*

180 Participants submitted daily test results to the study team by scanning a picture of the test  
181 cassette using the mobile app.

182

### 183 *2.4.3 Quantitative Survey*

184 Each of the TFA's seven constructs of acceptability was evaluated by one to three statements  
185 which participants rated on a five-point Likert scale (strongly disagree=1 to strongly agree=5).  
186 As a global measure of acceptability, participants were also asked whether, if given a choice,  
187 they would prefer to test for COVID-19 using the current PCR regimen or test daily with an at-  
188 home antigen test. We measured sociodemographic factors, including age, race/ethnicity, sex,  
189 education, living environment, and financial stability. Participants self-administered the 20-  
190 minute survey using REDCap, a secure web platform for administering online surveys.

191

### 192 *2.4.4 In-Depth Interview*

193 We conducted in-depth interviews with participants to more deeply understand their current and  
194 previous COVID-19 testing experiences and the acceptability of the daily COVID-19 testing



195 regimen. The interview guide was designed to assess the seven constructs in the TFA.  
196 Interviews were approximately 60 minutes long and conducted over Zoom by a team of four  
197 researchers experienced in qualitative interviewing (NN, BL, KM, and YW). Of the four  
198 researchers: two identified as Asian cis-gendered females, 1 White cis-gendered female, and 1  
199 White cis-gendered male; all four lived in New York City. All four were employed by Columbia  
200 University, which made rapid turnaround PCR testing available as needed in addition to random  
201 surveillance testing, and all were also using at-home antigen tests in their personal lives.  
202 Interviews were summarized in debrief forms immediately after completing the interviews and  
203 were audiorecorded and transcribed by a paid transcription service.

204

## 205 **2.5 Data Analysis**

206

### 207 *2.5.1 Quantitative analysis*

208 We summarized participant characteristics by estimating mean, standard deviation, frequency  
209 and proportion for all categorical and continuous sociodemographic and health factor variables,  
210 respectively. Additionally, we estimated the mean, standard deviation, median, and interquartile  
211 range (IQR) for each TFA construct measure and also estimated the frequency and proportion  
212 of participants who stated that they strongly agreed or agreed with each statement. We  
213 calculated overall adherence by taking the number of submitted test results and dividing it by  
214 the 21 days of the study. We categorized adherence into three groups and estimated the  
215 number and proportion of participants per group: 100% (tested daily), 50%-99% (tested at least  
216 every other day), and <50% (tested less than every other day). Finally, we calculated the  
217 frequency and proportion of participants who stated they would prefer testing daily with a rapid  
218 antigen test versus their current PCR regimen if given the choice.

219

### 220 *2.5.2 Qualitative analysis*

221 Interview transcripts were analyzed by a team of three researchers in Dedoose using Template  
222 Analysis, which is appropriate for studies using a priori themes and exploring perspectives of  
223 different groups in an organizational context (17). We initiated data analysis with a top-down  
224 approach, using the seven constructs in the TFA to create an organizational template. One  
225 member of the research team created a preliminary codebook by reading through interview  
226 debrief forms and identifying subconstructs within each of the TFA constructs. With the seven  
227 TFA constructs listed as parent codes and the subconstructs as child codes, the initial codebook  
228 was applied to two interview transcripts in Dedoose. A second researcher then applied the  
229 preliminary codebook to two more interviews and the codebook was further discussed and  
230 refined. All three coders then re-coded the initial four interviews using the finalized codebook to  
231 maximize reliability across coders. The three coders then individually coded the remaining 11  
232 interviews, meeting on an ad hoc basis to resolve coding questions, and using memos to note  
233 emerging themes. The coders generated code reports for each TFA construct, identified key  
234 quotes for each construct and subconstruct, and held team meetings to discuss emergent  
235 themes that conceptualized how each construct either directly or indirectly influenced  
236 acceptability and adherence. Lastly, we created quote matrices for each construct and  
237 subconstruct using the identified key quotes organized by emergent themes.

238

## 239 **3.0 Results**

240

### 241 **3.1 Participant characteristics**

242 Of the 63 eligible Disney employees, we enrolled 31 participants who completed the online  
243 survey, of whom 15 also agreed to an in-depth interview between February-June 2021 (Table 1,  
244 Figure 1). The 15 interview participants were similar to the overall sample of the survey, with  
245 regard to sociodemographic and health factors and adherence.

246

## 247 **3.2 Adherence to daily testing regimen**

248 Mean adherence to the 21-day testing regimen was 88% with 43% of participants achieving  
249 100% adherence, 48% achieving 50-99% adherence, and 10% achieving less than 50%  
250 adherence (Table 2).

251

## 252 **3.3 Testing preference**

253 Most participants (71%) reported that if given the choice, they would prefer to test for COVID-19  
254 daily using an at-home antigen test than weekly using PCR, while 19% preferred PCR, and 10%  
255 preferred only testing when necessary (Table 2).

256

## 257 **3.4 Acceptability of the daily testing regimen**

258

### 259 *3.4.1 Affective Attitude*

260 Participants reported overall positive feelings about the intervention though only 58% agreed  
261 with the statement “I like using the test every day” (see Table 3 for mean and median Likert  
262 scale scores). The overwhelming feeling reported by participants was comfort and peace of  
263 mind (Table 4, Affective attitude 1). Testing negative gave them needed reassurance to go  
264 about their daily lives and participants reported feeling “liberated” to engage in everyday  
265 activities without fear of infecting others (Affective attitude 2, 3). Participants also described  
266 using the tests after engaging in a “high risk” activity or potentially being exposed to COVID-19  
267 (Affective attitude 3). Notably, a small number of participants described significant anxiety due  
268 to living with someone who was immunocompromised; for these participants, the ability to test  
269 daily or on demand provided significant mental health benefits (Affective attitude 4).

270

271 For some participants who struggled to incorporate testing into their daily routine or who had  
272 difficulty using the mobile app to capture and interpret their test result, daily testing was more

273 burdensome. In these cases, participants reported feeling dread when they remembered they  
274 still had to test or frustration at being repeatedly unable to scan in a test result through the  
275 mobile app (Burden 6, Opportunity cost 5).

276

### 277 *3.4.2 Burden*

278 More than half of participants disagreed with the statements “it is inconvenient to use the self-  
279 test every day” (61%) (Table 3). Most participants describing daily self-testing as very  
280 convenient compared to other testing options they experienced (e.g., large drive-through testing  
281 events early in March/April 2020 or mandatory testing offered by their employer). Even among  
282 participants who had access to weekly on-site testing at their workplace, most preferred the  
283 daily antigen test. These participants overwhelmingly described testing daily as fast and easy  
284 often noting that daily self-testing took less time overall than weekly PCR testing (Table 4,  
285 Burden 1); that they didn’t mind daily testing because they could test on their own schedule and  
286 get the results quickly (Burden 2) or incorporate self-testing into other established routines (e.g.,  
287 timing the 15-minute waiting period with a shower) (Burden 3); and that they did not find the  
288 daily swabs to be invasive (Burden 4). While some participants described mild discomfort from  
289 the daily swabbing, this was not a major burden.

290

291 In the minority were participants who acknowledged that while daily at-home antigen testing was  
292 more convenient than weekly PCR testing, they still preferred testing using PCR because of the  
293 mental energy required to self-administer the test (Burden 5). Other participants described  
294 difficulty incorporating testing into their daily routine and reported testing fatigue (Burden 6).

295

### 296 *3.4.3 Self-efficacy*

297 Participants reported that the self-test was easy to learn to use (90%) and results easy to  
298 understand (100%) (Table 3). However, only half of participants (55%) stated that they

299 developed a habit of testing for COVID-19 in their daily routine, with experiences adhering to  
300 daily testing varying widely across participants. While some participants reported feeling initially  
301 overwhelmed by the testing steps, nearly all reported mastering the steps after a few days of  
302 testing (Table 4, Self-efficacy 1, 2). Factors that supported daily adherence included developing  
303 strategies to streamline the testing process (Self-efficacy 2); incorporating the test into their  
304 daily routine (Self-efficacy 3, 4); and placing the test kit in a prominent location (Self-efficacy 3).  
305 In contrast, participants reported that changes to their daily routine and weekends were the  
306 greatest barrier to daily adherence (Self-efficacy 5, 6).

307

#### 308 *3.4.4 Opportunity Cost*

309 Most participants strongly agreed with the statement: “It is easy for me to find a time to use the  
310 test every day” (68%) (Table 3). Nonetheless, time was often described as the biggest  
311 opportunity cost to testing daily (Table 4, Opportunity cost 1, 2). Some participants attempted to  
312 minimize the time cost by multi-tasking (Burden 3) or spreading out the time commitment by  
313 setting up their test kit the night before (Self-efficacy 3). However, others reported that efforts to  
314 multi-task resulted in more time spent testing because they would lead to mistakes like missing  
315 the results window during and having to repeat the testing process again (Opportunity cost 1, 2,  
316 3). For other participants, access to strong internet and/or a good light source were additional  
317 opportunity costs to daily testing as the mobile app required a specific level of light to accurately  
318 interpret the test result (Opportunity cost 4, 5). Participants who struggled to upload a picture of  
319 their test result consequently described testing as a “daily hassle” and “frustrating”, negatively  
320 impacting their affective attitude about the testing regimen.

321

#### 322 *3.4.5 Ethicality*

323 Most participants agreed that it is ethical for an employer to require its employees to test  
324 regularly for COVID-19 (87%) (Table 3). However, a small minority believed that regular testing

325 should be a personal choice (10%) and a significant portion of participants believe that sharing  
326 test results should be a personal choice (42%). Many participants articulated how working long  
327 hours near other coworkers necessitated the need for routine testing and saw mandatory testing  
328 as a practical approach to keeping the workplace safe (Table 4, Ethicality 1, 2). Specifically,  
329 many used Utilitarian arguments to justify mandatory testing, saying that the small loss of  
330 privacy and autonomy was justified for “the greater good” of workplace safety (Ethicality 3, 4, 5).  
331 Others went further, stating that routine testing helped them fulfil their personal responsibility to  
332 keep their workplace safe, noting that they “didn’t want to be transmitters” and that giving  
333 someone else COVID would be “an unacceptable thing” (Ethicality 6). In contrast, a small  
334 number of participants believed mandatory workplace testing was not ethical as it infringed upon  
335 individual liberties. While these participants were personally willing to test regularly through their  
336 employer, they believed that coercive tactics should not be used to keep the workplace safe  
337 (Ethicality 7).

338  
339 While participants tended to feel strongly that requiring regular COVID-19 tests was either  
340 ethical or unethical, participants’ feelings about who should have access to test results and what  
341 this health information should be used for was more nuanced. Many agreed that test results  
342 should be reported to their employer to prevent the spread of infection should an employee test  
343 positive (Ethicality 8); however, some had concerns about who within their company should  
344 have access to results (Ethicality 9). Participants also had mixed feelings regarding whether  
345 COVID-19 test results should be shared with larger health organizations, such as state health  
346 departments or the Centers for Disease Control and Prevention (CDC). Most participants  
347 believed these were trusted entities and saw the benefit of sharing COVID-19 results for  
348 contact tracing, surveillance, and allocation of health services (Ethicality 10); however, this  
349 feeling was not universal, and some reported not trusting the CDC or worrying that the health  
350 department would limit their freedom if they tested positive (Ethicality 11, 12). Additionally, a

351 small number of participants believed test results should stay within their employer due to  
352 concerns about health information privacy, including fears that their health information could be  
353 sold or compromised (Ethicality 13, 14). At the same time, many participants liked the idea of  
354 their test results being automatically reported to their employer or doctor through a mobile app,  
355 as this would eliminate the need for a third party to handle test results (Ethicality 15).

356

### 357 *3.4.6 Coherence*

358 The majority of participants believed that testing for COVID-19 daily made sense to prevent the  
359 spread of COVID-19 at and beyond the workplace (77%) (Table 3). Support for daily testing was  
360 particularly strong for times when COVID-19 rates were increasing or high; in this context,  
361 regular testing was considered an effective and necessary strategy for monitoring infection rates  
362 and preventing COVID-19 transmission (Table 4, Coherence 1). Specifically, many participants  
363 believed the unique needs of the entertainment industry, which relies on non-replaceable people  
364 to fill specific roles, further necessitated a stricter approach to COVID-19 control to ensure that  
365 work would not be disrupted (Coherence 2). Many participants said they wish they had access  
366 to daily testing during the original peak of the pandemic in March and April of 2020 (Coherence  
367 3).

368

369 While support for regular testing was near universal during times when risk of COVID-19  
370 infection was perceived to be high (i.e., before vaccines were available, when rates of infection  
371 were still increasing), there was less agreement about when routine testing was no longer  
372 needed. Many participants thought it made sense to continue regular COVID-19 testing until  
373 there was more research available on the transmissibility of emerging COVID-19 variants and  
374 effectiveness of the COVID-19 vaccines (Coherence 5). Others preferred to listen to scientific  
375 recommendations from public health agencies to decide whether frequent testing made sense  
376 (Coherence 6). Some participants expressed increasing doubt that regular COVID-19 testing

377 was still necessary given that vaccines were widely available to all adults and rates of COVID-  
378 19 in the workplace and surrounding community were very low (Figure 1). One participant in a  
379 managerial position used a cost benefit analysis to argue that frequent testing did not make  
380 sense from a financial perspective given the low positivity rates (Coherence 7). Many believed  
381 testing did not make sense for vaccinated populations, but that it may be an alternative for those  
382 who did not wish to become vaccinated (Coherence 8).

383

### 384 *3.4.7 Perceived effectiveness*

385 Participants had high confidence in the effectiveness of a daily testing intervention with the  
386 majority reporting that they trusted the results of the at-home antigen test (81%) and nearly all  
387 expressing confidence that testing daily will keep the people they work with safe from COVID-19  
388 (90%) (Table 3). Whether participants perceived the daily testing intervention would keep the  
389 workplace safe depended on three factors: 1) whether they trusted the test results, 2) whether  
390 they believed their co-workers would be willing and able to test daily, and 3) whether they  
391 believed frequent testing would introduce any unintended consequences. Although the antigen  
392 test used in the study had not yet received FDA approval and was only for use in research  
393 settings, nearly all participants reported trusting the results, citing trust in Columbia University  
394 (which helped develop the test in collaboration with a biotechnology company), trust in Disney  
395 (their employer) to provide a safe and effective test, and trust in experts/scientists (Table 4,  
396 Perceived effectiveness 1, 2). Other participants drew on previous experience using similar at-  
397 home tests (e.g., home pregnancy tests, glucose monitoring, maintaining swimming pool pH) as  
398 reasons for trusting the results (Perceived effectiveness 3). One participant noted that they  
399 trusted the daily antigen test result more than weekly PCR because the antigen test result  
400 reflected current COVID-19 status while the PCR result reflected a status from 24-48 hours ago  
401 and could give a false sense of security (Perceived effectiveness 4). In contrast, a different  
402 participant reported trusting the antigen test result less than PCR because they had heard from



403 family and friends with medical training that antigen tests were not as accurate as PCR  
404 (Perceived effectiveness 5).

405  
406 While participants were generally confident in their own ability to successfully use the at-home  
407 antigen test, they were less confident about their co-workers' abilities, which they believed could  
408 undermine the effectiveness of the daily testing intervention. These concerns included not  
409 believing that their coworkers would obtain a sufficient swab sample and properly self-  
410 administer the test at home (Perceived effectiveness 6), believing that a test administered by a  
411 medical professional would be more accurate (Perceived effectiveness 7), and worry that the  
412 identity of the test taker and the test result could not be confirmed in a home setting (Perceived  
413 effectiveness 8). Finally, some participants raised concerns that a frequent testing regimen  
414 would lead to employees increasing risky behavior that could result in more COVID-19  
415 transmission (Opportunity cost 9, 10).

416

#### 417 **4.0 Discussion**

418

419 As the COVID-19 pandemic continues to evolve with the emergence of new variants (18,19),  
420 waning vaccine and natural immunity (20–22), advancements and setbacks in treatment options  
421 (23), and changing human behavior in response to these inputs (24,25), new strategies for  
422 controlling and adapting to COVID-19 are needed. The Delta and Omicron variants have  
423 brought heightened interest in at-home antigen self-testing and the Biden administration has  
424 responded with significant resources to rapidly increase the availability of antigen tests in the  
425 US beginning late January 2022. The extent to which this intervention will have a significant  
426 public health impact remains to be seen but will in part depend on whether, and if so, how,  
427 Americans will use these tests. However as of January 2022, to our knowledge no studies have

428 examined the acceptability of self-testing for COVID-19, including serial testing regimens that  
429 have been shown most effective at detecting cases.

430  
431 Our mixed-methods study on the acceptability of a serial testing regimen showed that daily  
432 testing using an at-home antigen COVID-19 test was acceptable in one employment context.  
433 Employees were willing and able to adhere to a daily testing regimen for up to 21 days, with  
434 75% of participants achieving adherence 90% or greater. In addition to reporting overall high  
435 acceptability and adherence, our study identified three key implementation challenges that must  
436 be addressed for antigen tests to reach their full public health potential.

437  
438 First, there is a significant need for educational campaigns to build lay user trust in the accuracy  
439 of at-home antigen tests and knowledge around when and how to use them, including how to  
440 act on test results (26). Of the seven constructs that comprise acceptability, coherence and  
441 perceived effectiveness were most salient and determined whether participants ultimately felt it  
442 “was worth it” to test for COVID-19 daily. Importantly with respect to coherence, participants  
443 expressed a willingness to tolerate burden (inconvenience, invasiveness), opportunity costs  
444 (time), threats to ethicality (loss of privacy) associated with daily testing when they perceived the  
445 threat of COVID-19 to be high (high coherence), but indicated that given testing fatigue, this  
446 tolerance would not last forever. In the face of declining cases and universal access to  
447 vaccination among adults, participants saw a time in the then near future when this testing  
448 frequency would no longer be necessary, rendering the intervention less acceptable. As shown  
449 in Figure 1, the study was implemented right before the emergence of the Delta variant when  
450 case numbers were decreasing, vaccination eligibility was extended to study participants, and  
451 the fear of COVID was palpably receding in the public domain and among our study  
452 participants. Respondents reported that daily at-home testing made less sense at this moment  
453 in the epidemic than it had one month earlier when case numbers were rising and vaccinations

454 were not yet approved. These findings highlight that people’s tolerance for testing intensities  
455 change based on their changing perceptions of risk. Users urgently need clear public health  
456 guidance around when and how frequently to use at-home antigen tests under different  
457 epidemiological conditions, including specific guidance around on- and off-ramps to different  
458 testing intensities (27).

459  
460 We also found that trust in the accuracy of the at-home antigen test was key to whether  
461 participants perceived that the intervention would be effective. While most participants reported  
462 trusting the results of the test, this trust was primarily grounded in trust in the institutions  
463 providing this test and not in scientific evidence supporting test accuracy. Yet given that antigen  
464 tests will be distributed and used outside of the employment context, educational campaigns are  
465 needed to build trust in the tests, including by increasing lay user knowledge about the accuracy  
466 of antigen tests for detecting when users are most infectious and able to transmit to others.  
467 Increasing user literacy around antigen testing for COVID-19 may be particularly important  
468 given emerging mixed evidence about the performance and accuracy of antigen tests with the  
469 Omicron variant, including concerns about tests being less sensitive (28–31) and slower to  
470 detect COVID-19 in the nose compared to other sites (32), which may erode trust in antigen  
471 tests and impact acceptability and adherence to testing regimens. This work will need to be  
472 ongoing and responsive to emerging information with each new variant and delivered across all  
473 communities to ensure that scale up antigen testing does not exacerbate existing health  
474 disparities (7,33).

475  
476 Second, we wish to highlight that any frequent testing campaign will generate an enormous  
477 amount of sensitive health data and there is currently no existing universal infrastructure for  
478 routinely capturing or reporting this information to relevant health authorities, health care  
479 providers, or institutions (e.g., employers, schools). The lack of a universal recording and

480 reporting system for at-home antigen test results that are test brand agnostic creates numerous  
481 challenges including 1) potentially biased statistics around COVID-19 infection rates due to  
482 millions of home antigen test results not being reported, with implications for public health  
483 surveillance and resource allocation (34–36); 2) sharing of COVID-19 test results through non-  
484 secure channels (e.g., text messages, emails) providing opportunities for privacy breaches (37–  
485 39); and 3) challenges for the delivery of anti-viral treatments for COVID-19 within three days  
486 after symptom-onset for maximum benefit, due to the lack of guidance on whether a positive  
487 home antigen test can be used to qualify for treatment (40,41). In our study, testing data was  
488 captured securely and systematically using a mobile app that recorded and interpreted the test  
489 result for the user; these data were only shared with the study team, but the app could be  
490 further developed to support secure sharing with other entities. Most participants in our study  
491 found the app to be acceptable, however using this app was not without challenges, and some  
492 participants experienced significant difficulty using the app daily due to lack of internet or smart  
493 phone operating system too old to support the app. In a less technology savvy population,  
494 comfort with smart phone technology may also be a significant barrier. Further, while nearly all  
495 participants were comfortable with tests results being shared with the research team and their  
496 employer, they expressed significant concern about results being shared with health or  
497 government entities aside from their own provider.

498  
499 Anticipating potentially more dangerous pandemics in the near future, the Biden administration  
500 has developed a five-pillar plan for pandemic preparedness that includes “transforming our  
501 medical defense [through] dramatically improving diagnostics” (Pillar 1) and “ensuring situational  
502 awareness about infectious disease threats for both early warning and real-time monitoring”  
503 (Pillar 2) (42). A connected at-home antigen test that could accurately capture tests results and  
504 share them with government and health authorities in real time would address both pillars,  
505 however significant work remains to be done to build public trust and acceptability in such a

506 system (43). Within the current pandemic, anecdotally, antigen test results are already being  
507 informally shared with institutions like schools and employers to support strategies like “test to  
508 stay” (testing to remain after exposure) and “test to return” (testing to end isolation or return  
509 after infection). To our knowledge, there has been little to no research done on how these  
510 results are currently being shared or stored; guidelines for best practices are urgently needed.

511  
512 Finally third, given that the COVID-19 and future pandemics may disproportionately and  
513 negatively affect low-income and marginalized communities, it is essential that serial testing  
514 interventions in the workplace and elsewhere be employed in ways that put equity at the  
515 forefront. Mandatory workplace testing policies have the potential to both protect the most  
516 vulnerable, front-line employees, but if instituted without proper protections, can also create  
517 negative unintended consequences that may disproportionately burden vulnerable populations.  
518 The acceptability of a daily testing regimen in this study population was likely influenced by the  
519 employment context, including already established norms around routine COVID-19 testing, and  
520 job security and benefits (e.g., health insurance, dedicated paid COVID-19 sick leave) available  
521 to participants in our study who were all employed full-time. Although we anticipated and probed  
522 for worries about job security or loss of income due to testing positive for COVID-19,  
523 hypothesizing that this could reduce acceptability and adherence to the intervention, no  
524 participants reported such concerns. Possibly because of their job security, participants also  
525 almost universally believed that mandatory COVID-19 testing in the workplace was ethical. In  
526 other employment contexts with less job and income protection, mandatory serial testing may  
527 be much less acceptable and could have harmful unintended consequences.

528

## 529 **5.0 Conclusion**

530

531 Our study contributed to the knowledge gap around the implementation of serial at-home rapid  
532 antigen testing regimens. This is the first study to our knowledge to evaluate the acceptability of  
533 a serial COVID-19 testing regimen with a connected test in an employment context and report  
534 on adherence to the intervention. Our study advanced the Theoretical Framework of  
535 Acceptability by developing quantitative measures of acceptability and identifying three critical  
536 barriers to the successful implementation of rapid antigen testing as a public health intervention.

537  
538 There were also a number of limitations. The study was implemented at a time of relatively low  
539 COVID worry as the number of cases was falling steeply and vaccines offered a promise of  
540 durable protection. This epidemiological context along with the COVID-19 vaccine exclusion  
541 criterion impacted our ability to enroll a larger number of study participants and limits the  
542 generalizability of the findings and our ability to reach saturation. However, low accrual  
543 highlighted that context is an understudied component of acceptability causing acceptability to  
544 vary across time. Generalizability may also be limited by the fact that the small study was  
545 conducted in Southern California in a politically liberal area with high support for COVID  
546 precautions and within a stable employment context. Participants were all fully employed at a  
547 large company (Disney), and race, education, and SES are not representative of the broader  
548 US population. The relatively high adherence to the intervention we report is likely an artifact of  
549 the study context and selection bias based on willingness to enroll in the parent daily testing  
550 study and participate in in-depth interviews about the experience; we would expect adherence  
551 to be lower in the real world. Finally, we only looked at serial testing in an employment setting,  
552 although serial testing has now been rolled out in other contexts. Additional studies are needed  
553 to build the evidence-base about the acceptability of and adherence to serial-testing regimens to  
554 evaluate their public health contribution to interrupting transmission.

555

556

557 **Works Cited**

558

- 559 1. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is  
560 secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv*. 2021 Jan  
561 1;7(1).
- 562 2. Ricks S, Kendall EA, Dowdy DW, Sacks JA, Schumacher SG, Arinaminpathy N.  
563 Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a  
564 modelling analysis. *BMC Med*. 2021 Dec 1;19(1):1–13.
- 565 3. McKay SL, Tobolowsky FA, Moritz ED, Hatfield KM, Bhatnagar A, LaVoie SP, et al.  
566 Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing  
567 Home Outbreak. *Ann Intern Med*. 2021 Jul 1;174(7):945–51.
- 568 4. Smith RL, Gibson LL, Martinez PP, Ke R, Mirza A, Conte M, et al. Longitudinal  
569 Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2  
570 Infection. *J Infect Dis [Internet]*. 2021 Sep 17 [cited 2022 Feb 2];224(6):976–82. Available  
571 from: <https://academic.oup.com/jid/article/224/6/976/6311835>
- 572 5. Surasi K, Cummings KJ, Hanson C, Kate Morris M, Salas M, Seftel D, et al. Effectiveness  
573 of Abbott BinaxNOW Rapid Antigen Test for Detection of SARS-CoV-2 Infections in  
574 Outbreak among Horse Racetrack Workers, California, USA - Volume 27, Number 11—  
575 November 2021 - Emerging Infectious Diseases journal - CDC. *Emerg Infect Dis*  
576 [Internet]. 2021 Nov 1 [cited 2022 Feb 2];27(11):2761–7. Available from:  
577 [https://wwwnc.cdc.gov/eid/article/27/11/21-1449\\_article](https://wwwnc.cdc.gov/eid/article/27/11/21-1449_article)
- 578 6. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to  
579 Permit the Safe Reopening of College Campuses in the United States. *JAMA Netw open*  
580 [Internet]. 2020 Jul 31 [cited 2022 Feb 2];3(7). Available from:  
581 <https://pubmed.ncbi.nlm.nih.gov/32735339/>
- 582 7. Dawson L, Kates J. Rapid Home Tests for COVID-19: Issues with Availability and Access

- 583 in the U.S. [Internet]. Kaiser Family Foundation. 2021 [cited 2022 Feb 2]. Available from:  
584 [https://www.kff.org/report-section/rapid-home-tests-for-covid-19-issues-with-availability-](https://www.kff.org/report-section/rapid-home-tests-for-covid-19-issues-with-availability-and-access-in-the-u-s-issue-brief/)  
585 [and-access-in-the-u-s-issue-brief/](https://www.kff.org/report-section/rapid-home-tests-for-covid-19-issues-with-availability-and-access-in-the-u-s-issue-brief/)
- 586 8. Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies  
587 for covid-19. *BMJ*. 2021 Feb 3;372.
- 588 9. GOV.UK. Order coronavirus (COVID-19) rapid lateral flow tests [Internet]. 2022 [cited  
589 2022 Feb 2]. Available from: <https://www.gov.uk/order-coronavirus-rapid-lateral-flow-tests>
- 590 10. The White House. Fact Sheet: The Biden Administration to Begin Distributing At-Home,  
591 Rapid COVID-19 Tests to Americans for Free [Internet]. 2022 [cited 2022 Feb 2].  
592 Available from: [https://www.whitehouse.gov/briefing-room/statements-](https://www.whitehouse.gov/briefing-room/statements-releases/2022/01/14/fact-sheet-the-biden-administration-to-begin-distributing-at-home-rapid-covid-19-tests-to-americans-for-free/)  
593 [releases/2022/01/14/fact-sheet-the-biden-administration-to-begin-distributing-at-home-](https://www.whitehouse.gov/briefing-room/statements-releases/2022/01/14/fact-sheet-the-biden-administration-to-begin-distributing-at-home-rapid-covid-19-tests-to-americans-for-free/)  
594 [rapid-covid-19-tests-to-americans-for-free/](https://www.whitehouse.gov/briefing-room/statements-releases/2022/01/14/fact-sheet-the-biden-administration-to-begin-distributing-at-home-rapid-covid-19-tests-to-americans-for-free/)
- 595 11. The White House. Press Briefing by White House COVID-19 Response Team and Public  
596 Health Officials [Internet]. 2021 [cited 2022 Feb 2]. Available from:  
597 [https://www.whitehouse.gov/briefing-room/press-briefings/2021/10/06/press-briefing-by-](https://www.whitehouse.gov/briefing-room/press-briefings/2021/10/06/press-briefing-by-white-house-covid-19-response-team-and-public-health-officials-60/)  
598 [white-house-covid-19-response-team-and-public-health-officials-60/](https://www.whitehouse.gov/briefing-room/press-briefings/2021/10/06/press-briefing-by-white-house-covid-19-response-team-and-public-health-officials-60/)
- 599 12. The White House. President Biden’s COVID-19 Plan [Internet]. 2021 [cited 2022 Feb 2].  
600 Available from: <https://www.whitehouse.gov/covidplan/>
- 601 13. Balas E, Boren S. Managing Clinical Knowledge for Health Care Improvement. *Yearb*  
602 *Med Inform*. 2000;1:65–79.
- 603 14. Grant J, Green L, Mason B. Basic research and health: a reassessment of the scientific  
604 basis for the support of biomedical science. *Res Eval* [Internet]. 2003 Dec 1 [cited 2022  
605 Feb 2];12(3):217–24. Available from:  
606 <https://academic.oup.com/rev/article/12/3/217/1535438>
- 607 15. Morris ZS, wooding S, Grant J. The answer is 17 years, what is the question:  
608 understanding time lags in translational research. *J R Soc Med* [Internet]. 2011 Dec [cited



- 609 2022 Feb 2];104(12):510–20. Available from: <https://pubmed.ncbi.nlm.nih.gov/22179294/>
- 610 16. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: An  
611 overview of reviews and development of a theoretical framework. *BMC Health Serv Res.*  
612 2017;
- 613 17. King N. Doing Template Analysis. *Qual Organ Res Core Methods Curr Challenges.* 2017  
614 Dec 9;426–50.
- 615 18. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid  
616 epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature.* 2022  
617 Jan 7;
- 618 19. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes  
619 among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern  
620 California. *MedRxiv Prepr [Internet].* 2022 Jan 11 [cited 2022 Feb 3]; Available from:  
621 <https://www.medrxiv.org/content/10.1101/2022.01.11.22269045v1>
- 622 20. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant  
623 Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med.* 2022  
624 Jan 12;
- 625 21. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Eg Al Ly HT, et al. Omicron  
626 extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature.*  
627 2021;602:654–656.
- 628 22. Straten K van der, Guerra D, Gils MJ van, Bontjer I, Caniels TG, Willigen HDG van, et al.  
629 Mapping the antigenic diversification of SARS-CoV-2. *MedRxiv Prepr [Internet].* 2022 Jan  
630 3 [cited 2022 Feb 3]; Available from:  
631 <https://www.medrxiv.org/content/10.1101/2022.01.03.21268582v1>
- 632 23. Annavajhala MK, Mohri H, Wang P, Nair M, Zucker JE, Sheng Z, et al. Emergence and  
633 expansion of SARS-CoV-2 B.1.526 after identification in New York. *Nature.* 2021 Aug  
634 24;597(7878):703–8.


- 635 24. Schneider CR, Dryhurst S, Kerr J, Freeman ALJ, Recchia G, Spiegelhalter D, et al.  
636 COVID-19 risk perception: a longitudinal analysis of its predictors and associations with  
637 health protective behaviours in the United Kingdom. *J Risk Res* [Internet]. 2021 [cited  
638 2022 Feb 3];24(3–4):294–313. Available from:  
639 <https://www.tandfonline.com/doi/abs/10.1080/13669877.2021.1890637>
- 640 25. Qin H, Sanders C, Prasetyo Y, Syukron M, Prentice E. Exploring the dynamic  
641 relationships between risk perception and behavior in response to the Coronavirus  
642 Disease 2019 (COVID-19) outbreak. *Soc Sci Med* [Internet]. 2021 Sep 1 [cited 2022 Feb  
643 3];285. Available from: <https://pubmed.ncbi.nlm.nih.gov/34388619/>
- 644 26. Woloshin S, Dewitt B, Krishnamurti T, Fischhoff B. Assessing How Consumers Interpret  
645 and Act on Results From At-Home COVID-19 Self-test Kits: A Randomized Clinical Trial.  
646 *JAMA Intern Med* [Internet]. 2022 Jan 31 [cited 2022 Feb 21]; Available from:  
647 <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2788656>
- 648 27. Peeling RW, Heymann DL, Teo Y-Y, Garcia PJ. Diagnostics for COVID-19: moving from  
649 pandemic response to control. *Lancet* [Internet]. 2022 Feb 19 [cited 2022 Feb  
650 23];399(10326):757–68. Available from:  
651 <http://www.thelancet.com/article/S0140673621023461/fulltext>
- 652 28. Adamson B, Sikka R, Wyllie AL, Premisrur P. Discordant SARS-CoV-2 PCR and Rapid  
653 Antigen Test Results When Infectious: A December 2021 Occupational Case Series.  
654 *MedRxiv Prepr* [Internet]. 2022 Jan 5 [cited 2022 Feb 3]; Available from:  
655 <https://www.medrxiv.org/content/10.1101/2022.01.04.22268770v1>
- 656 29. Schrom J, Marquez C, Pilarowski G, Wang G, Mitchell A, Puccinelli R, et al. Direct  
657 Comparison of SARS-CoV-2 Nasal RT-PCR and Rapid Antigen Test (BinaxNOW™) at a  
658 Community Testing Site During an Omicron Surge. *medRxiv* [Internet]. 2022 Jan 19 [cited  
659 2022 Feb 3];2022.01.08.22268954. Available from:  
660 <https://www.medrxiv.org/content/10.1101/2022.01.08.22268954v4>

- 661 30. FDA. Omicron Variant: Impact on Antigen Diagnostic Tests (As of 12/28/2021) [Internet].  
662 2021 [cited 2022 Feb 3]. Available from: [https://www.fda.gov/medical-](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests#omicronvariantimpact)  
663 [devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests#omicronvariantimpact)  
664 [covid-19-tests#omicronvariantimpact](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests#omicronvariantimpact)
- 665 31. Bekliz M, Adea K, Alvarez C, Essaidi-Laziosi M, Escadafal C, Kaiser L, et al. Analytical  
666 sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant.  
667 MedRxiv Prepr [Internet]. 2021 Dec 22 [cited 2022 Feb 3]; Available from:  
668 <https://www.medrxiv.org/content/10.1101/2021.12.18.21268018v1>
- 669 32. Marais G, Hsiao N, Iranzadeh A, Doolabh D, Enoch A, Chu C, et al. Saliva swabs are the  
670 preferred sample for Omicron detection. MedRxiv Prepr [Internet]. 2021 Dec 24 [cited  
671 2022 Feb 3]; Available from:  
672 <https://www.medrxiv.org/content/10.1101/2021.12.22.21268246v1>
- 673 33. Bilal U, Tabb LP, Barber S, Diez Roux A V. Spatial Inequities in COVID-19 Testing,  
674 Positivity, Confirmed Cases, and Mortality in 3 U.S. Cities : An Ecological Study. Ann  
675 Intern Med. 2021 Jul 1;174(7):936–44.
- 676 34. McLaughlin K. Growing use of home COVID-19 tests leaves health agencies in the dark  
677 about unreported cases [Internet]. PBS News Hour. 2021 [cited 2022 Feb 23]. Available  
678 from: [https://www.pbs.org/newshour/health/growing-use-of-home-covid-19-tests-leaves-](https://www.pbs.org/newshour/health/growing-use-of-home-covid-19-tests-leaves-health-agencies-in-the-dark-about-unreported-cases)  
679 [health-agencies-in-the-dark-about-unreported-cases](https://www.pbs.org/newshour/health/growing-use-of-home-covid-19-tests-leaves-health-agencies-in-the-dark-about-unreported-cases)
- 680 35. Kasakove S. At-Home Covid Tests Raise Questions About Accurately Counting Cases  
681 [Internet]. The New York Times. 2021 [cited 2022 Feb 23]. Available from:  
682 <https://www.nytimes.com/2021/12/30/us/at-home-rapid-covid-tests-cases.html>
- 683 36. Jean S, Burnham C-AD, Chapin K, Garner OB, Pai NP, Turabelidze G, et al. At-Home  
684 Testing for Infectious Diseases: The Laboratory Where You Live. Clin Chem [Internet].  
685 2022 [cited 2022 Feb 18];68(1):19–26. Available from:  
686 <https://academic.oup.com/clinchem/article/68/1/19/6490224>

- 687 37. Brennan Center for Justice. Evaluating the Privacy of Covid-19 At-Home Tests [Internet].  
688 2021 [cited 2022 Feb 3]. Available from: [https://www.brennancenter.org/our-](https://www.brennancenter.org/our-work/analysis-opinion/evaluating-privacy-covid-19-home-tests)  
689 [work/analysis-opinion/evaluating-privacy-covid-19-home-tests](https://www.brennancenter.org/our-work/analysis-opinion/evaluating-privacy-covid-19-home-tests)
- 690 38. U.S. Equal Employment Opportunity Commission. What You Should Know About COVID-  
691 19 and the ADA, the Rehabilitation Act, and Other EEO Laws [Internet]. 2021 [cited 2022  
692 Feb 3]. Available from: [https://www.eeoc.gov/wysk/what-you-should-know-about-covid-](https://www.eeoc.gov/wysk/what-you-should-know-about-covid-19-and-ada-rehabilitation-act-and-other-eeo-laws)  
693 [19-and-ada-rehabilitation-act-and-other-eeo-laws](https://www.eeoc.gov/wysk/what-you-should-know-about-covid-19-and-ada-rehabilitation-act-and-other-eeo-laws)
- 694 39. Ribeiro-Navarrete S, Saura JR, Palacios-Marqués D. Towards a new era of mass data  
695 collection: Assessing pandemic surveillance technologies to preserve user privacy.  
696 Technol Forecast Soc Change [Internet]. 2021 Jun 1 [cited 2022 Feb 23];167:120681.  
697 Available from: </pmc/articles/PMC8019834/>
- 698 40. CDC. Self-Testing [Internet]. 2022 [cited 2022 Feb 3]. Available from:  
699 <https://www.cdc.gov/coronavirus/2019-ncov/testing/self-testing.html>
- 700 41. Wroe EB, Seung KJ, Baker BK, Farmer PE. Test and treat: a missing link in the global  
701 fight against COVID-19. Lancet Glob Heal [Internet]. 2022 Feb 1 [cited 2022 Feb  
702 23];10(2):e181–2. Available from:  
703 <http://www.thelancet.com/article/S2214109X21005684/fulltext>
- 704 42. The White House. American Pandemic Preparedness: Transforming Our Capabilities.  
705 2021;
- 706 43. Kadam R, White W, Banks N, Katz Z, Dittrich S, Kelly-Cirino C. Target Product Profile for  
707 a mobile app to read rapid diagnostic tests to strengthen infectious disease surveillance.  
708 PLoS One [Internet]. 2020 Jan 1 [cited 2022 Feb 3];15(1). Available from:  
709 <https://pubmed.ncbi.nlm.nih.gov/31995628/>

710

## COVID-19 Pandemic Context Timeline



Figure